An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment (NCT06883240)

🧪 Interventions in This Study

• Von Willebrand Factor Concentrates (DRUG)
• Von Willebrand Factor Concentrates and Factor VIII Concentrates (DRUG)
• Factor VIII Concentrates (DRUG)
• Recombinant Activated Factor VII (DRUG)
• Activated Prothrombin Complex Concentrate (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (26 Sites)

Showing the first 25 of 26 sites.

• UC Davis — Sacramento, California
• University of Minnesota Medical Center — Minneapolis, Minnesota
• Washington University School of Medicine — St Louis, Missouri
• UZ Leuven Gasthuisberg — Leuven,
• The Hospital for Sick Children — Toronto, Ontario
• McGill University Health Center — Montreal, Quebec
• IPS SURA Industriales Medellín — Medellín,
• Hopital Claude Huriez - CHU Lille — Lille,
• Groupe Hospitalier Necker Enfants Malades — Paris,
• Universitätsklinikum Bonn — Bonn,
• Gerinnungszentrum Rhein-Ruhr;Gerinnungsambulanz — Duisburg,
• Hämophiliezentrum Med. Klinik III/Institut für Transfusionsmedizin — Frankfurt/M.,
• Universita' Degli Studi La Sapienza-Ist.Di Ematologia — Rome, Lazio
• IRCCS Ca' Granda Ospedale Maggiore Policlinico — Milan, Lombardy
• AOU Careggi — Florence, Tuscany
• Kurume University Hospital — Fukuoka,
• Tokyo Medical University Hospital — Tokyo,
• Erasmus MC — Rotterdam,
• Instytut Hematologii i Transfuzjologii — Warsaw,
• Charlotte Maxeke Johannesburg Academic Hospital — Johannesburg,
• Hospital Universitario la Paz — Madrid,
• Hospital Universtiario Virgen del Rocio — Seville,
• Sahlgrenska Universitetssjukhuset — Gothenburg,
• St Thomas' Hospital — London,
• Great Ormond Street Hospital — London,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Von Willebrand Disease, Type 3

• Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A — Orange, California
• A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease — Sacramento, California

Explore by condition: All Von Willebrand Disease, Type 3 clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.